Assessment of the comparative effectiveness of individual AADs on CV hospitalization and mortality end points is not possible with the current evidence
AIM To assess , through a systematic review , evidence for the effects of antiarrhythmic drugs ( AADs ) on  cardiovascular ( CV ) hospitalization and mortality .
Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
Epidemiological , experimental studies and post hoc analyses of r and omized trials suggested that n-3 polyunsaturated fatty acids ( PUFA ) and statins could be beneficial in chronic heart failure . Two double-blind , placebo-controlled , r and omized clinical trials investigated the efficacy and safety of n-3 PUFA 1 g daily ( R1 ) and rosuvastatin 10 mg daily ( R2 ) in patients with heart failure . In total , 6975 and 4574 patients were r and omized in R1 and R2 , respectively ; the main reason for excluding patients from R2 being the open-label administration of statin treatment . Primary end points were death , and death or admission to hospital for cardiovascular reasons .  n-3 PUFA , but not rosuvastatin , significantly decreased the two co primary end points : 56 and 44 patients needed to be treated with n-3 PUFA for a median duration of 3.9 years to avoid one death or one cumulative event . Both drugs were safe and were tolerated . A simple and safe treatment with n-3 PUFA provides a beneficial advantage in patients with heart failure in a context of usual care
Assessment of the comparative effectiveness of individual AADs on CV hospitalization and mortality end points is not possible with the current evidence
AIM To assess , through a systematic review , evidence for the effects of antiarrhythmic drugs ( AADs ) on  cardiovascular ( CV ) hospitalization and mortality .